0.7542

1.92% 0.0142

After Hours: .75 -0.0042 -0.56%

Spero Therapeutics Inc (SPRO)

Overview News Price History Option Chain Financials Discussions Forecast

Spero Therapeutics Inc stock is traded at $0.7542, with a volume of 35,941. It is up +1.92% in the last 24 hours and down -2.17% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Previous Close:

$0.74

Open:

$0.74

24h Volume:

35,941

Relative Volume:

0.19

Market Cap:

$39.19M

Revenue:

$76.19M

Net Income/Loss:

$-1.61M

P/E Ratio:

75.42

EPS:

0.01

Net Cash Flow:

$28.98M

1W Performance:

+30.60%

1M Performance:

-2.17%

6M Performance:

-41.31%

1Y Performance:

-49.72%

1-Day Range:

$0.74

$0.786

1-Week Range:

$0.522

$0.829

52-Week Range:

$0.5052

$1.72

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name

Spero Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

857-242-1600

Address

675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA

Employee

Twitter

@spero_tx

Next Earnings Date

2025-03-19

Latest SEC Filings

SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SPRO Spero Therapeutics Inc	0.7542	39.19M	76.19M	-1.61M	28.98M	0.01
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy
Dec-16-20	Initiated	Berenberg	Buy
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight
Nov-27-17	Initiated	BofA/Merrill	Neutral
Nov-27-17	Initiated	Oppenheimer	Outperform
Nov-27-17	Initiated	Stifel	Buy

View All

Spero Therapeutics Inc Stock (SPRO) Latest News

Apr 12, 2025

Prudential Financial Inc. Acquires Shares of 49,200 Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 12, 2025

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges - Investing.com Canada

Apr 09, 2025

Spero Therapeutics stock hits 52-week low at $0.51 amid challenges By Investing.com - Investing.com South Africa

Apr 09, 2025

Apr 05, 2025

Spero Therapeutics, Inc. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Spero Therapeutics, Inc. - MarketScreener

Apr 05, 2025

Apr 02, 2025

Virtu Financial LLC Makes New $47,000 Investment in Spero Therapeutics, Inc. (NASDAQ:SPRO) - Defense World

Apr 02, 2025

Mar 29, 2025

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate - Yahoo Finance

Mar 29, 2025

Mar 28, 2025

Earnings call transcript: Spero Therapeutics Q4 2024 misses EPS forecast - Investing.com India

Mar 28, 2025